More Images
Moderna released study results today showing its new Omicron-specific booster increased antibodies against the coronavirus by a factor of 5, even against some of the newer and more worrisome variants.

The company also today asked the FDA to authorize the use of the vaccine. The company said shipments of this vaccine could begin as early as this summer.

The booster in development contains both Moderna’s original COVID-19 vaccine and one specifically designed to target the more recent BA.4 and BA.5 Omicron subvariants. Head over to WebMD to read the full story.